Date | Title | Description |
30.07.2025 | NewAmsterdam Pharma Presents Positive Data from BROADWAY Trial Demonstrating Statistically Significant Reductions in Key Alzheimer’s Disease Biomarkers at AAIC 2025 | -- Pre-specified analysis shows obicetrapib significantly reduced absolute levels of plasma p-tau217, a key biomarker of Alzheimer’s disease pathology, in both the full analysis set (p=0.0019) and in ApoE4 carriers (p=0.0215), supporting CE... |
05.07.2025 | FAIR PLAY MENARINI INTERNATIONAL AWARD, A WAVE OF EMOTIONS MARKS THE 29TH EDITION | FIESOLE, Italy, July 5, 2025 /PRNewswire/ -- A night suspended between history and legend, dedicated to the most authentic values of ethics and fair play. In the timeless setting of the Roman Theatre of Fiesole, where culture met sport, the... |
02.07.2025 | FAIR PLAY MENARINI INTERNATIONAL AWARD: THE 29TH EDITION OFFICIALLY BEGINS | FLORENCE, Italy, July 2, 2025 /PRNewswire/ -- Medals and records alone are not enough to make history and actions, choices, and the way one conducts oneself, can speak louder than any achievement. With this spirit, the 29th edition of the F... |
29.05.2025 | New Frontiers in Cancer Treatment: Elacestrant and Kidney Cancer Monitoring | In the relentless battle against cancer, innovation is the sword and shield. Two recent developments shine a light on this ongoing fight: the promising data surrounding elacestrant for breast cancer and the completion of a significant kidne... |
23.05.2025 | Menarini Group Presents Updated Data Underscoring the Combinability of Elacestrant (ORSERDU®) in Patients with ER+, HER2- Metastatic Breast Cancer (mBC) at the ASCO 2025 Annual Meeting | Preliminary efficacy analysis from the elacestrant plus everolimus and ribociclib cohorts of the ELEVATE study, along with updated safety data from additional cohorts of elacestrant plus targeted therapy combination arms, will be presented.... |
15.05.2025 | DeepL's HIPAA Compliance: A New Era for Healthcare Communication | In a world where communication is key, DeepL has taken a giant leap. The company recently announced its compliance with the Health Insurance Portability and Accountability Act (HIPAA). This is not just a box checked; it’s a commitment to se... |
14.05.2025 | Campaign Asia-Pacific Supercharges Campaign360 2025 with Expanded Theatre Stages! | HONG KONG, May 14, 2025 /PRNewswire/ -- Get ready for Campaign360 2025 on May 27-28 at the iconic Marina Bay Sands in Singapore! This year, Campaign Asia-Pacific, owned by Haymarket Media Limited, is elevating brand marketing with expanded ... |
20.03.2025 | Menarini Group Announces Collaboration with VisualDx to Aid in Identifying People Who May Have Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) | BPDCN is an aggressive hematologic malignancy with a historically poor prognosis
VisualDx is a clinical decision support system used by more than 2,300 hospitals, clinics, and medical schools around the world
VisualDx's system seeks to enha... |
15.03.2025 | Insilico Medicine: $110 Million (Series E) Raised For Advancing AI-Based Drug Discovery | Insilico Medicine (see Pulse 2.0 profile here), a clinical-stage generative AI-driven drug discovery company, announced that it has successfully secured a $110 million Series E financing led by a private equity fund of Value Partners Group ... |
13.03.2025 | Insilico Medicine Raises $110M in Series E Financing | Insilico Medicine, a Cambridge, MA-based clinical-stage generative artificial intelligence (AI)-driven drug discovery company, raised $110M in Series E funding.
The round was led by Value Partners Group (HKG:0806) with participation from ne... |
10.02.2025 | The Double-Edged Sword of Technology: Scams and Sports in the Modern Age | In the digital age, technology is a double-edged sword. It can uplift or ensnare. Recent events in Italy illustrate this stark reality. A sophisticated scam targeting high-profile individuals has emerged, showcasing the dark side of technol... |
10.02.2025 | Artificial Intelligence Action Summit in Paris as AI scam in Italy comes to light. | In a sophisticated scam that has recently come to light, several prominent Italian business figures were targeted by fraudsters impersonating Italian Defense Minister Guido Crosetto. The perpetrators utilized advanced techniques, including ... |
11.01.2025 | The Future of Oncology: Menarini and Insilico's Groundbreaking Partnership | In the world of oncology, innovation is the lifeblood that fuels hope. The Menarini Group and Insilico Medicine have forged a partnership that promises to reshape cancer treatment. Their latest agreement, announced on January 10, 2025, mark... |
11.01.2025 | Menarini Group and Insilico Medicine Enter a Second Exclusive Global License Agreement for an AI Discovered Preclinical Asset Targeting High Unmet Needs in Oncology | This is the second asset Menarini Group has inlicensed from Insilico Medicine which was discovered through their generative AI platform, similar to the preclinical stage KAT6 inhibitor (MEN2312) licensed a year ago and which advanced rapidl... |
10.01.2025 | Menarini Group and Insilico Medicine Enter a Second Exclusive Global License Agreement for an AI Discovered Preclinical Asset Targeting High Unmet Needs in Oncology | This is the second asset Menarini Group has inlicensed from Insilico Medicine which was discovered through their generative AI platform, similar to the preclinical stage KAT6 inhibitor (MEN2312) licensed a year ago and which advanced rapidl... |
16.12.2024 | Menarini Group announces Positive Topline Data from Pivotal Phase 3 BROADWAY & TANDEM Clinical Trials Evaluating Obicetrapib and the Fixed-Dose Combination Obicetrapib with Ezetimibe 10 mg | – Both pivotal studies achieved primary endpoints of LS mean reduction in LDL-C on top of maximally tolerated lipid-modifying therapies with high statistical significance (p |
12.12.2024 | Menarini Group and MEDSIR Present the Phase III Study ADELA: A New Therapeutic Strategy for Advanced Breast Cancer | ADELA, an international phase III study being conducted across multiple countries, combines elacestrant with everolimus to treat advanced ER+/HER2- breast cancer with ESR1 mutations, aiming to delay disease progression.
The study was presen... |
02.12.2024 | FAIR PLAY MENARINI - THE CHAMPIONS TELL THEIR STORIES: TALES OF SPORT AND LIFE TRIUMPH AT THE TALK SHOW | FLORENCE, Italy, Dec. 2, 2024 /PRNewswire/ -- Thoughts, anecdotes and unexpected backstories providing an insight into sport. It was an emotion-packed evening for the talk show Fair Play Menarini – The Champions Tell their Stories. Fair pla... |
26.11.2024 | Menarini Group Presents New and Expanded Data at the 2024 San Antonio Breast Cancer Symposium Reinforcing the Role of ORSERDU® (Elacestrant) for Patients with ER+, HER2- Advanced or Metastatic Breast ... | Real-world evidence bolsters the efficacy of ORSERDU for the treatment of patients with ER+/HER2- ESR1-mut advanced or mBC.
Updated results of elacestrant in combination with abemaciclib show favorable efficacy regardless of the ESR1 mutati... |
29.07.2024 | Menarini Announces Positive Topline Data from Pivotal Phase 3 BROOKLYN Clinical Trial Evaluating Efficacy, Safety and Tolerability of Obicetrapib in Patients with Heterozygous Familial Hypercholestero... | -- Achieved primary endpoint of LS mean reduction in LDL-C on top of maximally tolerated lipid modifying therapies at week 12 with statistically significant reduction (p |
05.07.2024 | FAIR PLAY MENARINI INTERNATIONAL AWARD, A MAGICAL NIGHT AT FIESOLE FOR THE GRAND FINALE | FLORENCE, Italy, July 5, 2024 /PRNewswire/ -- A finale to remember: the sporting legends delighted the packed terraces of the Roman Theatre in Fiesole, bringing the curtain down on the 28th Fair Play Menarini International Award. Yesterday,... |
05.07.2024 | FAIR PLAY MENARINI INTERNATIONAL AWARD, A MAGICAL NIGHT AT FIESOLE FOR THE GRAND FINALE | FLORENCE, Italy, July 5, 2024 /PRNewswire/ -- A finale to remember: the sporting legends delighted the packed terraces of the Roman Theatre in Fiesole, bringing the curtain down on the 28th Fair Play Menarini International Award. Yesterday,... |
03.07.2024 | FAIR PLAY MENARINI INTERNATIONAL AWARD, THE CELEBRATIONS FOR THE 28TH EDITION BEGIN | FLORENCE, Italy, July 3, 2024 /PRNewswire/ -- The 28th edition of the Fair Play Menarini International Award is about to kick off. Preparations are under way in the cities of Florence and Fiesole to host the numerous champions who will ligh... |
20.06.2024 | LEGENDARY STRIKER SAMUEL ETO'O AMONG THE WINNERS OF THE 28TH EDITION OF THE FAIR PLAY MENARINI INTERNATIONAL AWARD | FLORENCE, Italy, June 20, 2024 /PRNewswire/ -- The Members of the Board of the Fair Play Menarini Foundation, Antonello Biscini, Valeria Speroni Cardi and Ennio Troiano, are delighted to welcome another champion to the roster of 2024 award ... |
05.06.2024 | FAIR PLAY MENARINI INTERNATIONAL AWARD ANNOUNCING THE WINNERS OF THE 28th EDITION AT THE CONI HEADQUARTERS | From Fabio Cannavaro to Marco Belinelli, Ambra Sabatini, Clemente Russo and many others: here are the names of the new champions of ethics, loyalty and respect
ROME, June 5, 2024 /PRNewswire/ -- The wait is finally over - new sporting stars... |
24.05.2024 | Menarini Group Presents Updated Data from ELECTRA and ELEVATE Combination Studies of Elacestrant (ORSERDU®) in Patients with ER+, HER2- Metastatic Breast Cancer (mBC) at the ASCO 2024 Annual Meeting | The ELECTRA and ELEVATE studies were designed to overcome different resistance mechanisms and improve patient outcomes with oral-oral combination options.
Updated results from the ELECTRA study, evaluating elacestrant in combination with ab... |
24.04.2024 | RELIFE BY A. MENARINI CHAMPIONS PERSONAL CHOICE IN AESTHETIC TREATMENTS, ENCOURAGING SELF-CARE AND SELF-LOVE | - The choice is the individual's hand to treat oneself with love and care, where judgments and negative opinions have no place in personal beauty journeys.
KUALA LUMPUR, Malaysia, April 24, 2024 /PRNewswire/ -- RELIFE, the dermatology and a... |
05.01.2024 | Menarini Group and Insilico Medicine Enter Global Exclusive License Agreement for Novel KAT6 Inhibitor for Potential Breast Cancer Treatment and Other Oncology Indications | KAT6 is an emerging target in hormone sensitive breast tumors and other cancers. Overexpression of KAT6A/B correlates with poor clinical outcomes in patients with ER+/HER2- breast cancer – the most common subtype.
The molecule has demonstra... |
12.12.2023 | Menarini Group Presented Initial Safety and Efficacy Data from Phase 1b/2 ELEVATE and ELECTRA Combination Studies of ORSERDU® (Elacestrant) in Patients with ER+, HER2- Metastatic Breast Cancer (mBC) a... | ELEVATE and ELECTRA studies were designed with the objective to overcome different treatment resistance mechanisms and enhance patient outcomes with oral-oral combination options.
A preliminary analysis of data in the phase 1b part of the E... |
21.11.2023 | Menarini Group Announces New Data on ORSERDU® (elacestrant) at the 2023 San Antonio Breast Cancer Symposium and on ELZONRIS® (tagraxofusp-erzs) at the 65th American Society of Hematology Annual Meetin... | - Data spans eleven presentations across both solid tumors and hematologic malignancies, providing added understanding of the potential benefit these therapies bring to patients
- ORSERDU data reinforce its key role in the treatment of ER+,... |
08.11.2023 | Menarini Group and SciClone Pharmaceuticals Announce Exclusive Sub-Licensing Collaboration to Develop and Commercialize ORSERDU® (Elacestrant) in China to Address Advanced or Metastatic Breast Cancer | ORSERDU is the first treatment specifically approved for patients with ER+, HER2- advanced or metastatic breast cancer tumors that harbor ESR1 mutations, representing the first innovation in endocrine therapy in nearly 20 years.
ESR1 mutati... |
20.09.2023 | European Commission Approves Menarini Group's ORSERDU® (Elacestrant) for the Treatment of Patients with ER+, HER2- Locally Advanced or Metastatic Breast Cancer with an Activating ESR1 Mutation | Each year in Europe more than 550,000 patients are diagnosed with breast cancer, of whom 70% have estrogen receptor (ER)-positive disease¹; more than 147,000 breast cancer patients in Europe die annually from the disease²
ORSERDU is the fir... |
30.08.2023 | The Menarini Group Announces ELZONRIS® (Tagraxofusp) Designated as an Orphan Drug for BPDCN by Japanese Ministry of Health, Labor and Welfare | Japanese Ministry of Health, Labor and Welfare grants Orphan Drug Designation to tagraxofusp for blastic plasmacytoid dendritic cell neoplasm (BPDCN)
FLORENCE, Italy and NEW YORK, Aug. 30, 2023 /PRNewswire/ -- The Menarini Group ("Mena... |
21.07.2023 | Menarini Group Receives Positive CHMP Opinion Recommending EC Approval of ORSERDU® (Elacestrant) for the Treatment of Patients with ER+, HER2- Locally Advanced or Metastatic Breast Cancer with an Acti... | Each year in Europe more than 550,000 patients are diagnosed with breast cancer, of whom 70% have estrogen receptor (ER)-positive disease¹; more than 147,000 breast cancer patients in Europe die annually from the disease²
If approved by the... |
26.05.2023 | Menarini Group Shares New Analysis from EMERALD Clinical Study of ORSERDU® (Elacestrant) in Metastatic Breast Cancer at ASCO 2023 | ORSERDU (elacestrant) was approved by the FDA in January 2023 for estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer with ESR1-mutations (ESR1-mut) that are found i... |
15.05.2023 | BOTTICELLI, THE INQUIETUDE AND THE BEAUTY - Menarini presents in Florence its latest art monograph, dedicated to the symbol of the Italian Renaissance | FLORENCE, Italy, May 15, 2023 /PRNewswire/ -- Successful artist, sensitive interpreter of the culture of his time and author of extraordinarily relevant works, Sandro Botticelli was a master of beauty. With his "Venuses," he unkno... |
09.05.2023 | Menarini Group Announces New Data on Elacestrant at 2023 ESMO Breast Cancer Congress and 2023 ASCO Annual Meeting | FLORENCE, Italy and NEW YORK, May 9, 2023 /PRNewswire/ -- The Menarini Group ("Menarini"), a leading Italian pharmaceutical and diagnostics company, and Stemline Therapeutics ("Stemline"), a wholly-owned subsidiary of th... |
30.01.2023 | Stemline Therapeutics, a subsidiary of Menarini Group, Receives U.S. FDA Approval for ORSERDUTM (elacestrant) as the First and Only Treatment Specifically Indicated for Patients with ESR1 Mutations in... | ESR1 mutations are present in up to 40% of ER+, HER2- advanced or metastatic breast cancers.
ESR1 mutations are a known driver of resistance to standard endocrine therapy, and so far, have been difficult to treat.
ORSERDU is the first endoc... |
19.12.2022 | Carrick Therapeutics and The Menarini Group Announce Clinical Trial Collaboration to Evaluate Samuraciclib and Elacestrant Combination | Carrick to execute Phase 2 clinical trial in patients with CDK4/6i resistant HR+, HER2- metastatic breast cancer
DUBLIN and FLORENCE, Italy, Dec. 19, 2022 /PRNewswire/ -- Carrick Therapeutics, an oncology-focused biopharmaceutical company d... |
01.12.2022 | Menarini Group Presents Updated Results from Pivotal Phase 3 EMERALD Trial at the 2022 San Antonio Breast Cancer Symposium (SABCS) that Demonstrate Elacestrant's PFS Increases with Duration of Prior C... | Elacestrant demonstrated longer progression-free survival (PFS) vs SOC endocrine therapy with medians up to 8.6 months, positively associated with the duration of prior treatment with CDK4/6 inhibitors
Elacestrant side effects were manageab... |
27.09.2022 | Context Therapeutics trims pipeline, cuts down on spending to conserve cash | To survive the current market conditions, Philadelphia-based Context Therapeutics has resorted to cost-cutting, a hiring freeze and pipeline pruning.
The company, which develops treatments for breast and gynecologic... |
19.08.2022 | Menarini Group's Elacestrant Marketing Authorization Application Accepted for Review by the European Medicines Agency (EMA) for the Treatment of ER+/HER2- Advanced or Metastatic Breast Cancer | Elacestrant, if approved, would be the first oral selective estrogen receptor degrader (SERD) to be available for patients suffering from second-line (2L) and third-line (3L) ER+/HER2- advanced or metastatic breast cancer in the European Un... |
11.08.2022 | Menarini Group's Elacestrant Granted Priority Review by the U.S. FDA for Patients with ER+/HER2- Advanced or Metastatic Breast Cancer | Elacestrant, if approved, would be the first oral selective estrogen receptor degrader (SERD) to be available for patients suffering from 2L and 3L ER+/HER2- advanced or metastatic breast cancer
Submission supported by results from the pivo... |
02.08.2022 | Context Therapeutics and The Menarini Group Announce Clinical Trial Collaboration and Supply Agreement to Evaluate ONA-XR and Elacestrant Combination | Preclinical data support the potential of ONA-XR plus estrogen receptor degraders in endocrine resistant disease models
Context to initiate Phase 1b/2 clinical trial in Q4 2022
PHILADELPHIA and FLORENCE, Italy, Aug. 02, 2022 (GLOBE NEWSWIRE... |
02.08.2022 | Context Therapeutics and The Menarini Group Announce Clinical Trial Collaboration and Supply Agreement to Evaluate ONA-XR and Elacestrant Combination | Preclinical data support the potential of ONA-XR plus estrogen receptor degraders in endocrine resistant disease models
Context to initiate Phase 1b/2 clinical trial in Q4 2022
PHILADELPHIA and FLORENCE, Italy, Aug. 2, 2022 /PRNewswire/ -- ... |
29.06.2022 | NewAmsterdam Pharma and the Menarini Group Sign Licensing Deal to Commercialize Obicetrapib in Europe | - Combines NewAmsterdam's lead clinical program obicetrapib with Menarini's deep cardiovascular disease and regional expertise
- Total deal value of over €1 billion; including €142.5 million upfront payment and committed R&D funding plu... |
23.06.2022 | Menarini Group and Radius Health Submit New Drug Application to the U.S. FDA for Elacestrant | Intended for potential treatment of ER+/HER2- advanced or metastatic breast cancer patients
Priority Review requested; if accepted, anticipate an 8-month FDA review
Positive EMERALD study data previously announced on October 20, 2021
First,... |
06.06.2022 | Menarini Group and Radius Health, Inc. present a subgroup analysis from the elacestrant pivotal phase 3 EMERALD clinical trial at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting | Subgroup analysis of patients with no prior chemotherapy in EMERALD: A phase 3 trial evaluating elacestrant, an investigational oral selective estrogen receptor degrader (SERD), vs. investigator's choice of endocrine monotherapy for ER+/HER... |
26.05.2022 | Menarini inaugurates new regional headquarters in Dubai, UAE | The pharmaceutical group, present in 140 countries in the world, aims to raise standard of patient healthcare across the Middle East and Africa (MEA) region with innovative products and breakthrough research
DUBAI, UAE, May 26, 2022 /PRNews... |
20.05.2022 | Menarini Group and Radius Health, Inc. announce publication of elacestrant pivotal Phase 3 EMERALD clinical trial data in the Journal of Clinical Oncology | Emerald study met both its primary end points of Progression-free survival (PFS) in overall population and in ESR1 mutated patients
PFS rate at 12 months with elacestrant was 22.32% vs. 9.42% with SOC in the overall population, and 26.76% v... |
22.12.2021 | Karyopharm and Menarini Group Enter into Exclusive License Agreement to Commercialize NEXPOVIO® (selinexor) in Europe and Other Key Global Territories | - Menarini Group Obtains Exclusive Rights to Commercialize NEXPOVIO for the Treatment of Hematologic and Solid Tumor Oncology Indications in Europe (including the United Kingdom), Latin America and Other Key Countries
- Karyopharm to Receiv... |
09.12.2021 | Positive EMERALD Trial Results for Elacestrant Presented at San Antonio Breast Cancer Symposium 2021 | - Trial met both primary endpoints demonstrating statistically significant and clinically meaningful extension of progression free survival (PFS) as monotherapy vs. standard of care (SoC) endocrine therapy in overall population and estrogen... |
04.11.2021 | Menarini Receives FDA Orphan Drug Designation for SEL24/MEN1703, a first in class, dual PIM/FLT3 inhibitor for the Treatment of Acute Myeloid Leukemia | FLORENCE, Italy, Nov. 4, 2021 /PRNewswire/ -- The Menarini Group announced today that the U.S. Food and Drug Administration (FDA) granted orphan drug designation (ODD) to SEL24/MEN1703 for the treatment of Acute Myeloid Leukemia (AML). SEL2... |
01.06.2021 | Menarini Announces New SEL24/MEN1703 Clinical Data from DIAMOND-01 Trial
USA - English USA - English France - Français Italia - Italiano Deutschland - Deutsch España - español | |
09.04.2021 | Menarini Pills of Art Junior project launched, video clips made by the younger generations for children and teenagers
USA - English USA - English | |
07.12.2020 | Menarini Announces Results from New Preclinical Studies on MEN1611 for the Treatment of Breast Cancer at the 2020 San Antonio Breast Cancer Symposium
USA - English
USA - English
France - Français
... | |
04.05.2020 | Italy’s Menarini Group to acquire Stemline Therapeutics for $677M | Shares of Stemline were up 153.7% on the Nasdaq by late morning following the news. Menarini is a privately held company.
Stemline won Food and Drug Administration approval in December 2018 for Elzonris (tagraxofusp-erzs), a drug used to tr... |
01.04.2020 | Coronavirus Business Tracker: How The Private Sector Is Fighting The Covid-19 Pandemic | Alain Mérieux, founder of BioMérieux.AFP via Getty Images |
22.09.2013 | Menarini Acquires Silicon Biosystems | Pharma giant Menarini acquired Silicon Biosystems, a Bologna, Italy-based startup focused on the isolation of rare cancer cells.
The amount of the transaction was not disclosed.
The agreement will allow Silicon Biosystems to accelerate its ... |
- | Italy’s Menarini Group to acquire Stemline Therapeutics for $677M | An Italian pharmaceutical and diagnostics company plans to acquire a New York-based firm with a drug used to treat a rare blood cancer.
Florence, Italy-based Menarini Group said Monday that it would spend up to $677 million to buy Stemline ... |